CHICAGO, Oct. 1 /PRNewswire/ -- Abiant, Inc., an Illinois based company specializing advanced bio-imaging to accelerate and improve drug development and disease diagnosis, announces the successful closing of a $600,000 private placement. Lead investor Heartland Angels, an angel network specializing in early-stage technology, syndicated the round with Kettering Medical Center and other participants. Abiant has developed partnerships with large pharmaceutical companies and with academic collaborators. The company has obtained an exclusive license from New York University School of Medicine to image processing technology that has enabled the early and accurate identification of dementias.
Ed Maier, owner of the Maier Consulting Group and a former Senior Partner with Arthur Andersen, and Rick Mace, Vice President, Clinical Services Division of Kettering Medical Center, have joined Abiant's Board of Directors as part of this Offering. We are excited about supporting a technology that will change the way we monitor CNS drug effects in the clinical testing process", said Ron Kirschner, M.D., President of Heartland Angels. Dawn Matthews, President and CEO of Abiant, said "With this financing, we are adding two valuable strategic partners and the resources to expand the application of our imaging technology. We are eager to continue the progress created by the dedication and shared vision of our team, customers, and stakeholders." O.B. Parrish, Chairman of Abiant's Board, added "This financing provides Abiant with the opportunity to grow and capitalize on its technology".
About Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to
provide a sensitive biomarker of drug effects and disease progression. The
imaging information, which includes biochemical, functional, and structural
measurements, can be used to accelerate or reduce risk of decision making
in both drug development and disease treatment. The Company's focus area
|SOURCE Abiant, Inc.|
Copyright©2007 PR Newswire.
All rights reserved